Lilly's Lechleiter Talks Innovation During Obama's Consultation With CEOs
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly's CEO was the sole representative of the biopharmaceutical industry participating in President Obama's meeting with the leaders of 20 large U.S. corporations.
You may also be interested in...
Innovation “Crisis” And Health Care Reform: Lilly CEO Urges Change In Focus
Lilly CEO John Lechleiter is urging policy makers to focus on the "I word" - Innovation - in the context of the health care reform debate
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.